Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases

 Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases

Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases

Shots:

  • Inflammasome to receive up to $160M up front, R&D milestone, commercialization milestone with royalties on sales of the developed product. The companies will co-develop up to three therapies for patients with retinal disease
  • The focus of the agreement is to strengthen Boehringer’s retinal portfolio by combining with Inflammasome’s IVT drug delivery technology. The collaboration will lead to the reduction in eye disease by delivering biodegradable gel therapies into the eye
  • Boehringer has a pipeline of ophthalmology developing next-generation therapies progressed up to P-II stage targeted for macular degeneration, diabetic retinal diseases and beyond, utilizing Inflammasome’s IVT implants to complement its portfolio

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Space well Interiors

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post